Elafin
Also known as: Elafin, Elastase-specific inhibitor, PI3, SKALP, Skin-derived antileukoprotease, Trappin-2, WFDC2
Source Elafin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Elafin is a human serine protease inhibitor belonging to the whey‑acidic‑protein (WAP) family. It is produced by epithelial cells and naturally limits neutrophil elastase and proteinase‑3 activity while displaying antimicrobial properties. Research is exploring its use as a therapeutic agent for inflammatory lung disease, intestinal disorders, vascular injury, and postoperative inflammation, as well as a potential antimicrobial against resistant bacteria.
Mechanism of Action
Elafin binds tightly to the active sites of neutrophil elastase and proteinase‑3, competitively blocking substrate cleavage. The C‑terminal WAP domain also confers defensin‑like antimicrobial activity against bacteria, fungi and possibly viruses. In immune cells, elafin can down‑regulate pro‑inflammatory cytokines such as TNF‑α and influence transcription factors that drive inflammation. As a transglutaminase substrate, it can become cross‑linked to extracellular matrix proteins, reinforcing mucosal barriers.
What the Research Shows
Pre‑clinical studies in mice and other animal models have shown that augmenting elafin levels reduces lung inflammation, limits reperfusion injury, and protects against vascular damage. In models of colitis and other gut inflammatory conditions, intravenous or intracolonic delivery of elafin attenuated tissue injury and promoted barrier repair. Gene‑transfer experiments demonstrated activity against Pseudomonas aeruginosa in the lung. A Phase I trial in humans reported good tolerability, and Phase II trials are investigating postoperative inflammation after major surgeries. Reviews highlight altered elafin expression in chronic lung disease, psoriasis, and intestinal disorders, suggesting biomarker and therapeutic relevance.
Reported Benefits
Animal data indicate that elafin can diminish neutrophil‑driven tissue damage, lower pro‑inflammatory cytokine production, and directly kill or inhibit growth of pathogenic microbes. In lung, gut and vascular injury models, treated subjects showed reduced histological damage and improved functional outcomes. Early human testing showed the protein to be well tolerated, supporting its potential as a multi‑modal anti‑inflammatory and antimicrobial agent.
Limitations of the Evidence
Most efficacy evidence comes from animal models; definitive clinical benefit in humans has not yet been demonstrated. The exact molecular pathways underlying its antimicrobial effects remain incompletely characterized. Phase II trials are ongoing, so efficacy and safety data are limited. Variable expression of elafin in diseases such as psoriasis complicates its use as a universal biomarker, and optimal dosing regimens have not been established.
Safety Considerations
The completed Phase I study reported no serious adverse events and described elafin as well tolerated, but comprehensive safety profiling is pending further clinical trials. Potential concerns include immunogenicity with repeated protein administration and unknown long‑term effects on protease balance. Route‑specific safety (e.g., inhalation versus intravenous) has not been fully evaluated, and caution is advised until larger studies confirm its safety profile.
How It Is Administered
Elafin has been investigated via inhalation for lung disease, intravaginal application for mucosal protection, intravenous infusion for systemic inflammation, and topical formulations for skin or gut mucosal delivery. Experimental approaches also include gene‑transfer vectors and mucosal sprays to target the intestinal surface. All formulations remain investigational and are delivered in controlled research settings.
Routes of Administration
Goals & Uses
- Vaginal dysbiosis / preterm birth preventionReproductive / AntimicrobialLow
- Cardiac surgery-associated inflammationPerioperative CytoprotectionModerate
- Antimicrobial defenseAntimicrobial Peptide ActivityModerate
- Acute lung injury / ARDS protectionAnti Inflammatory / Tissue ProtectionModerate
- Inflammatory bowel diseaseGastroenterologyLow
- Prevention of graft‑versus‑host diseaseImmunomodulationLow
- Inflammatory skin disease treatmentAnti‑inflammatoryModerate
- Cystic fibrosis airway inflammationPulmonary Anti InflammatoryModerate
Contraindications
- Known hypersensitivity to elafin or excipientsAllergic / ImmunologicHigh
- Known hypersensitivity to elafin or formulation excipientsAllergyHigh
- Severe coagulopathyHematologicModerate
Adverse Effects
- Local skin irritationDermatologicalCommon
- Injection site reactionsLocalUncommon
- Hypersensitivity reactionImmunologicUncommon
- Airway irritationPulmonaryUnknown
- Immunogenicity / antibody formationImmunologicUnknown
- Transient hypotensionCardiovascularUncommon
Drug Interactions
- Anticoagulants (e.g., heparin, warfarin)Low
- Recombinant human DNase (dornase alfa)Low
Population Constraints
- Patients with active malignancyOncologyRelative
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveRelative
- Pregnant womenReproductiveRelative
- Pediatric patients <12 yearsAgeRelative
Regulatory Status
- European UnionInvestigationalEarly‑phase clinical trials ongoing; not authorized for marketing.
- United StatesInvestigationalInvestigational New Drug (IND) applications submitted for dermatologic and transplant indications.
- United KingdomInvestigationalMHRA has not approved any elafin therapeutic product; UK academic groups involved in elafin research.
No FDA‑approved therapeutic formulation; investigated in early‑phase trials for psoriasis, cystic fibrosis airway inflammation, and graft‑versus‑host disease.
Evidence & Sources
- Journal ArticleModerateDi YP, Kuhn JM, Mangoni ML2024-01-01T00:00:00.000000Z
- Journal ArticleModerateMatwiejuk M, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateShaw L, Wiedow O2011-01-01T00:00:00.000000Z
- Journal ArticleModerateHo S, Pothoulakis C, Koon HW2013-01-01T00:00:00.000000Z
- Journal ArticleModerateDeraison C, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateSallenave JM2002-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of molecule is elafin?
Elafin is a small human protein that belongs to the whey‑acidic‑protein (WAP) family and functions as a serine protease inhibitor with additional antimicrobial activity.
How does elafin reduce inflammation?
By tightly inhibiting neutrophil elastase and proteinase‑3, elafin prevents excessive proteolysis. It also down‑regulates cytokines such as TNF‑α and modulates transcription factors that drive inflammatory gene expression.
What conditions are currently being studied for elafin therapy?
Research focuses on inflammatory lung diseases, colitis and other gut disorders, vascular injury, postoperative inflammation after major surgery, and its role as an antimicrobial against resistant bacteria.
Is elafin approved for clinical use?
No. Elafin is an investigational compound; it has completed a Phase I safety trial and is undergoing Phase II studies but has not received regulatory approval for any indication.
What is Elafin?
Elafin is a human serine protease inhibitor belonging to the whey‑acidic‑protein (WAP) family. It is produced by epithelial cells and naturally limits neutrophil elastase and proteinase‑3 activity while displaying antimicrobial properties. Research is exploring its use as a therapeutic agent for inflammatory lung disease, intestinal disorders, vascular injury, and postoperative inflammation, as well as a potential antimicrobial against resistant bacteria.
What is Elafin used for?
Elafin is educationally associated with: Vaginal dysbiosis / preterm birth prevention, Cardiac surgery-associated inflammation, Antimicrobial defense, Acute lung injury / ARDS protection, Inflammatory bowel disease, Prevention of graft‑versus‑host disease, Inflammatory skin disease treatment, Cystic fibrosis airway inflammation. Educational only — not medical advice.
How is Elafin administered?
Recorded routes of administration: Inhalation, Intravaginal, Intravenous, Topical.
What are the potential side effects of Elafin?
Reported adverse effects include: Local skin irritation, Injection site reactions, Hypersensitivity reaction, Airway irritation, Immunogenicity / antibody formation, Transient hypotension. This list is not exhaustive — consult a qualified clinician.
Who should avoid Elafin?
Recorded contraindications: Known hypersensitivity to elafin or excipients, Known hypersensitivity to elafin or formulation excipients, Severe coagulopathy. Consult a qualified clinician before use.